<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626392</url>
  </required_header>
  <id_info>
    <org_study_id>M10-241</org_study_id>
    <nct_id>NCT00626392</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia</brief_title>
  <acronym>ASA EFFECTS</acronym>
  <official_title>Multicenter, Randomized, Double-Blind, Parallel, Acetylsalicylic Acid (ASA) Run-In Study to Evaluate the EFFECTS of Acetylsalicylic Acid on Niaspan®-Induced Flushing in Subjects With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study was to assess the effect of aspirin (ASA) on niacin
      extended-release (NER)-induced flushing in subjects with dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment</measure>
    <time_frame>From Baseline to end of Week 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Moderate or Greater Flushing Events Per Subject Per Week Overall During 4 Weeks of Niacin Extended-release (NER) Treatment</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>NER 500; ASA run-in, ASA coadmin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NER 500; ASA Pbo run-in, ASA coadmin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NER 500; ASA Pbo run-in, ASA Pbo coadmin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NER 1000; ASA run-in, ASA coadmin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NER 1000; ASA Pbo run-in, ASA coadmin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NER 1000; ASA Pbo run-in, ASA Pbo coadmin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>niacin extended-release (NER)</intervention_name>
    <description>Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period</description>
    <arm_group_label>NER 500; ASA run-in, ASA coadmin</arm_group_label>
    <arm_group_label>NER 500; ASA Pbo run-in, ASA coadmin</arm_group_label>
    <arm_group_label>NER 500; ASA Pbo run-in, ASA Pbo coadmin</arm_group_label>
    <arm_group_label>NER 1000; ASA run-in, ASA coadmin</arm_group_label>
    <arm_group_label>NER 1000; ASA Pbo run-in, ASA coadmin</arm_group_label>
    <arm_group_label>NER 1000; ASA Pbo run-in, ASA Pbo coadmin</arm_group_label>
    <other_name>Niaspan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin (ASA)</intervention_name>
    <description>325 mg tablets administered once daily</description>
    <arm_group_label>NER 500; ASA run-in, ASA coadmin</arm_group_label>
    <arm_group_label>NER 500; ASA Pbo run-in, ASA coadmin</arm_group_label>
    <arm_group_label>NER 1000; ASA run-in, ASA coadmin</arm_group_label>
    <arm_group_label>NER 1000; ASA Pbo run-in, ASA coadmin</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin placebo (ASA Pbo)</intervention_name>
    <description>Tablets administered once daily</description>
    <arm_group_label>NER 500; ASA Pbo run-in, ASA coadmin</arm_group_label>
    <arm_group_label>NER 500; ASA Pbo run-in, ASA Pbo coadmin</arm_group_label>
    <arm_group_label>NER 1000; ASA Pbo run-in, ASA coadmin</arm_group_label>
    <arm_group_label>NER 1000; ASA Pbo run-in, ASA Pbo coadmin</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be 18 years of age or older.

          -  If female, subject is either not of childbearing potential, defined as postmenopausal
             for at least one year or surgically sterile, or is of childbearing potential and must
             agree to practice birth control for the duration of the study.

          -  Have dyslipidemia as demonstrated by laboratory results.

        Exclusion Criteria:

          -  Have glycosylated hemoglobin (HbA1c) &gt;/= 9.0%.

          -  Have nephrotic syndrome, dysproteinemias, or severe renal failure (glomerular
             filtration rate [GFR] &lt; 30 mL/minute, as calculated from creatinine clearance).

          -  Have had unstable angina or an acute myocardial infarction (MI) within three months of
             the Screening Visit.

          -  Have had severe peripheral artery disease as evidenced by intermittent claudication
             within three months of the Screening Visit.

          -  Have had uncontrolled cardiac arrhythmias within three months of the Screening Visit.

          -  Have symptomatic heart failure defined as dyspnea at rest or with exertion (mild
             peripheral edema is not exclusionary).

          -  Have a systolic blood pressure measurement of &gt; 180 mmHg or a diastolic blood pressure
             measurement of &gt; 110 mmHg at the Screening or Baseline Visit.

          -  Have active gout or uric acid &gt;/= 11 mg/dL.

          -  Have a history of hepatitis (acute or chronic), obstructive liver disease, or alanine
             aminotransferase (ALT; serum glutamic pyruvic transaminase [SGPT]) or aspartate
             aminotransferase (AST; serum glutamic oxaloacetic transaminase [SGOT]) values &gt;/= 1.3
             times the upper limit of normal (ULN) at the Screening Visit.

          -  Have creatine phosphokinase (CPK) &gt;/= 3 x ULN at the Screening Visit.

          -  Have used an investigational study drug or participated in an investigational study
             within 30 days of the Screening Visit.

          -  Have a health condition or laboratory abnormality (inclusive of clinically significant
             laboratory results at Screening Visit), which, in the opinion of the Investigator, may
             be adversely affected by the procedures or study medications in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roopal Thakkar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>N. Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penndel</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colleyville</city>
        <state>Texas</state>
        <zip>76034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Thakkar RB, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJ. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs. 2009;9(2):69-79. doi: 10.2165/00129784-200909020-00001.</citation>
    <PMID>19331435</PMID>
  </results_reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <results_first_submitted>April 16, 2009</results_first_submitted>
  <results_first_submitted_qc>July 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2009</results_first_posted>
  <last_update_submitted>August 26, 2009</last_update_submitted>
  <last_update_submitted_qc>August 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Scott Krause, Associate Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 47 study sites in the United States between February and April, 2008.</recruitment_details>
      <pre_assignment_details>This study had a 1-week run-in (acetylsalicylic acid [ASA] 325 mg or ASA placebo [Pbo] once daily) prior to 4 weeks of niacin extended-release (NER) plus ASA/ASA Pbo coadministration. Ten of 277 randomized subjects discontinued before run-in due to withdrawal of consent (4), lost to follow-up (4), protocol violation (1), and other (1).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NER 500; ASA run-in, ASA Coadmin</title>
          <description>Aspirin (ASA) 325 mg daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
        <group group_id="P2">
          <title>NER 500; ASA Pbo run-in, ASA Coadmin</title>
          <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
        <group group_id="P3">
          <title>NER 500; ASA Pbo run-in, ASA Pbo Coadmin</title>
          <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
        <group group_id="P4">
          <title>NER 1000; ASA run-in; ASA Coadmin</title>
          <description>Aspirin (ASA) 325 mg daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
        <group group_id="P5">
          <title>NER 1000; ASA Pbo run-in, ASA Coadmin</title>
          <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
        <group group_id="P6">
          <title>NER 1000; ASA Pbo run-in, ASA Pbo Coadmin</title>
          <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Run-in Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="41"/>
                <participants group_id="P6" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Coadministration Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="41"/>
                <participants group_id="P6" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NER 500; ASA run-in, ASA Coadmin</title>
          <description>Aspirin (ASA) 325 mg daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
        <group group_id="B2">
          <title>NER 500; ASA Pbo run-in, ASA Coadmin</title>
          <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
        <group group_id="B3">
          <title>NER 500; ASA Pbo run-in, ASA Pbo Coadmin</title>
          <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
        <group group_id="B4">
          <title>NER 1000; ASA run-in, ASA Coadmin</title>
          <description>Aspirin (ASA) 325 mg daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
        <group group_id="B5">
          <title>NER 1000; ASA Pbo run-in, ASA Coadmin</title>
          <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 325 mg 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
        <group group_id="B6">
          <title>NER 1000; ASA Pbo run-in, ASA Pbo Coadmin</title>
          <description>Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration (4 weeks)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="43"/>
            <count group_id="B5" value="41"/>
            <count group_id="B6" value="44"/>
            <count group_id="B7" value="256"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Includes only those subjects who entered the coadministration period and received at least one dose of study medication.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" spread="10.62"/>
                    <measurement group_id="B2" value="49.0" spread="10.48"/>
                    <measurement group_id="B3" value="51.5" spread="12.58"/>
                    <measurement group_id="B4" value="53.7" spread="12.4"/>
                    <measurement group_id="B5" value="54.8" spread="11.08"/>
                    <measurement group_id="B6" value="52.3" spread="12.45"/>
                    <measurement group_id="B7" value="52.8" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Includes only those subjects who entered the coadministration period and received at least one dose of study medication.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="124.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="132.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Includes only those subjects who entered the coadministration period and received at least one dose of study medication.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="256.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment</title>
        <description>The maximum severity of flushing events subjects experienced during Week 1 of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.</description>
        <time_frame>From Baseline to end of Week 1</time_frame>
        <population>All subjects in the modified intent-to-treat population, defined as all subjects who took at least 1 dose of study medication and who had at least 1 entry in the Flushing Assessment Tool e-diary (n = 251).</population>
        <group_list>
          <group group_id="O1">
            <title>Any Acetylsalicylic Acid</title>
            <description>Pooled arms that received acetylsalicylic acid (ASA) 325 mg during run-in and/or coadministration.</description>
          </group>
          <group group_id="O2">
            <title>No Acetylsalicylic Acid</title>
            <description>Pooled arms that received acetylsalicylic acid placebo (ASA Pbo) during run-in and coadministration.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment</title>
          <description>The maximum severity of flushing events subjects experienced during Week 1 of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.</description>
          <population>All subjects in the modified intent-to-treat population, defined as all subjects who took at least 1 dose of study medication and who had at least 1 entry in the Flushing Assessment Tool e-diary (n = 251).</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None/mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons. P-values &lt;= 0.05 were reported as statistically significant.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment</title>
        <description>The maximum severity of flushing events subjects experienced during 4 weeks of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.</description>
        <time_frame>4 weeks</time_frame>
        <population>All subjects in the modified intent-to-treat population, defined as all subjects who took at least 1 dose of study medication and who had at least 1 entry in the Flushing Assessment Tool e-diary (n = 251).</population>
        <group_list>
          <group group_id="O1">
            <title>Any Acetylsalicylic Acid</title>
            <description>Pooled arms that received acetylsalicylic acid (ASA) 325 mg during run-in and/or coadministration.</description>
          </group>
          <group group_id="O2">
            <title>No Acetylsalicylic Acid</title>
            <description>Pooled arms that received acetylsalicylic acid placebo (ASA Pbo) during run-in and coadministration.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment</title>
          <description>The maximum severity of flushing events subjects experienced during 4 weeks of NER treatment was categorized as none, mild, moderate, severe, or very severe using the Flushing Assessment Tool via an e-diary. Flushing was assessed daily and the percentage of subjects with maximum flushing severity in each category was calculated.</description>
          <population>All subjects in the modified intent-to-treat population, defined as all subjects who took at least 1 dose of study medication and who had at least 1 entry in the Flushing Assessment Tool e-diary (n = 251).</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None/Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment</title>
        <description>Subjects assessed the severity of flushing events on a 10-point numeric rating scale of 1-3 (mild), 4-6 (moderate), 7-9 (severe), and 10 (very severe) using the Flushing Assessment Tool via an e-diary. For subjects who did not experience flushing, a score of 0 was assigned. Flushing was assessed daily.</description>
        <time_frame>4 weeks</time_frame>
        <population>All subjects in the modified intent-to-treat population, defined as all subjects who took at least 1 dose of study medication and who had at least 1 entry in the Flushing Assessment Tool e-diary (n = 251).</population>
        <group_list>
          <group group_id="O1">
            <title>Any Acetylsalicylic Acid</title>
            <description>Pooled arms that received acetylsalicylic acid (ASA) 325 mg during run-in and/or coadministration.</description>
          </group>
          <group group_id="O2">
            <title>No Acetylsalicylic Acid</title>
            <description>Pooled arms that received acetylsalicylic acid placebo (ASA Pbo) during run-in and coadministration.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Maximum Severity of Flushing Events Overall During 4 Weeks of Niacin Extended-release (NER) Treatment</title>
          <description>Subjects assessed the severity of flushing events on a 10-point numeric rating scale of 1-3 (mild), 4-6 (moderate), 7-9 (severe), and 10 (very severe) using the Flushing Assessment Tool via an e-diary. For subjects who did not experience flushing, a score of 0 was assigned. Flushing was assessed daily.</description>
          <population>All subjects in the modified intent-to-treat population, defined as all subjects who took at least 1 dose of study medication and who had at least 1 entry in the Flushing Assessment Tool e-diary (n = 251).</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="2.86"/>
                    <measurement group_id="O2" value="5.1" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Moderate or Greater Flushing Events Per Subject Per Week Overall During 4 Weeks of Niacin Extended-release (NER) Treatment</title>
        <description>Flushing was assessed daily using the Flushing Assessment Tool via an e-diary and the mean number of flushing events per subject per week considered moderate or greater in severity was calculated. Flushing events were rated by the subject using a categorical scale of mild, moderate, severe, or very severe.</description>
        <time_frame>4 weeks</time_frame>
        <population>All subjects in the modified intent-to-treat population, defined as all subjects who took at least 1 dose of study medication and who had at least 1 entry in the Flushing Assessment Tool e-diary (n = 251).</population>
        <group_list>
          <group group_id="O1">
            <title>Any Acetylsalicylic Acid</title>
            <description>Pooled arms that received acetylsalicylic acid (ASA) 325 mg during run-in and/or coadministration.</description>
          </group>
          <group group_id="O2">
            <title>No Acetylsalicylic Acid</title>
            <description>Pooled arms that received acetylsalicylic acid placebo (ASA Pbo) during run-in and coadministration.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Moderate or Greater Flushing Events Per Subject Per Week Overall During 4 Weeks of Niacin Extended-release (NER) Treatment</title>
          <description>Flushing was assessed daily using the Flushing Assessment Tool via an e-diary and the mean number of flushing events per subject per week considered moderate or greater in severity was calculated. Flushing events were rated by the subject using a categorical scale of mild, moderate, severe, or very severe.</description>
          <population>All subjects in the modified intent-to-treat population, defined as all subjects who took at least 1 dose of study medication and who had at least 1 entry in the Flushing Assessment Tool e-diary (n = 251).</population>
          <units>Number of Events per Subject per Week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.64"/>
                    <measurement group_id="O2" value="0.8" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Any Acetylsalicylic Acid</title>
          <description>Pooled arms that received acetylsalicylic acid (ASA) 325 mg during run-in and/or coadministration.</description>
        </group>
        <group group_id="E2">
          <title>No Acetylsalicylic Acid</title>
          <description>Pooled arms that received acetylsalicylic acid placebo (ASA Pbo) during run-in and coadministration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Esophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="119"/>
                <counts group_id="E2" subjects_affected="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10-1">Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Provide Abbott at least sixty (60) days prior to submission for review, Abbott shall return comments within sixty (60) days of receipt of draft. Proposed draft shall be delayed an additional sixty (60) days in addition to the Review Period.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Specialist</name_or_title>
      <organization>Abbott</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

